Cases and Conversations: Sequencing Strategies in Relapsed and Refractory CLL (ASH 2026) - Sep 26, 2026 - Pres time: Dec 11, 2026; 07:00 PM - 10:00 PM; Location: MCCNO - La Nouvelle A-B; "Pivotal phase 3 readouts — AMPLIFY (acalabrutinib + venetoclax ± obinutuzumab), CLL17, BRUIN CLL-313/-314 (pirtobrutinib), CELESTIAL-TN (sonrotoclax + zanubrutinib), and MAJIC — have reshaped both the treatment armamentarium and the decision framework around fixed-duration vs continuous therapy. Real-world data show persistent gaps in molecular testing, treatment selection, and toxicity management. This Medical Crossfire® session uses focused didactic primers paired with moderated expert debate to examine the frontline decision points clinicians face every day, with attention to molecular testing, fixed-duration vs continuous therapy, MRD-guided approaches, and proactive AE management."
Clinical • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia
|
|
Alexey V. Danilov, MD, PhD; Seema Ali Bhat, MD; Jeff Sharman, MD
|